How Forma is working to show the sickle cell community it’s in for the long haul
Forma is prioritizing sickle cell patient engagement with a focus on policy advocacy and COVID-19 safety
With early data coming in for its sickle cell program, Forma is prioritizing patient engagement, with a focus on policy advocacy and COVID-19 safety.
As early clinical evidence for its sickle cell disease candidate grows, Forma is prioritizing building relationships with the patient community, with a focus on long-term policy goals and COVID-19 safety protections.
Forma Therapeutics Inc. (NASDAQ:FMTX) CEO Frank Lee said it’s crucial for companies to prove that their commitment to patient engagement goes beyond clinical trial recruitment and drug sales. “We’re a relative newcomer to the space. Building relationships takes many years of being there for the community,” said Lee.
A key step was appointing